2017-02-002 + 2017-02-003 - CeNPs4HCC - CERIA NANOPARTICLES FOR USE IN THE TREATMENT OF HEPATOCELLULAR (CeNPs4HCC)
Acronim & Gínjol codes
CeNPs4HCC
2017-02-002 + 2017-02-003
Main technology offer
Increase of overall survival of treated rats with induced HCC in a remarkably way, together with a strong reduction of the proliferation of the cancer cells
Ownership
Cerdanyola del Vallès, Spain
2004
Institut Català de Nanociència i Nanotecnologia (ICN2)
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
Market Data
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs predominantly as metastasis from the colon or in patients with underlying chronic liver disease and cirrhosis. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. The threat of HCC is expected to continue to grow in the coming years. The peak incidence of HCC associated with hepatitis C virus infection has not yet occurred. There is also a growing problem with cirrhosis, which develops in the setting of nonalcoholic fatty liver disease, or nonalcoholic steatohepatitis (NASH). NASH typically develops in the setting of obesity, type 2 diabetes, dyslipidemia, and hypertension, and it will undoubtedly remain a significant problem, given the modern obesity epidemics.
0
0
0
Development of CeNP as therapeutic agent in HCC
HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. The threat of HCC is expected to continue to grow in the coming years. The peak incidence of HCC associated with hepatitis C virus infection has not yet occurred.
Hepatocellular carcinoma (HCC)
Funding
Industrial partner interested in the codevelopment of the technology and/or acquisition of the license
Technology Status
Research teams has conjugated CeO2NPs and have tested them in rats undergoing induced HCC. Results show a remarkable effect of these CeO2NPs in cell proliferation reduction and rat survival with HCC.
EP application filed on April 2016 at the European Patent Office and extended into PCT in april 2017. The patent claims both the new CeO2NPs formulation and its use in HCC treatment.
Although several attempts were done to find a partner, finally any company was interested in the project. The institutions did not enter into national phases and the patent was abandoned before enterin into national phases.
Additional information
Patents: WO2017162666A1 ; PCT/EP2017/056688 - Date: Oct 12th, 2017 Status: Granted URL: https://patents.google.com/patent/WO2017162666A1/en
CeO2NPs have antitumor activity and improve survival in HCC rats. CeO2NPs were also reported to manipulate tumor-stromal interactions to detract tumor progression and invasion while benefiting stromal cells.